About us

Calypso Biotech is an innovative biopharmaceutical company based in Geneva, Switzerland and founded in 2013 as a spin-off from Merck Serono, a global leader in auto-immune diseases and biologics. Calypso Biotech was initially financed through a 2.5 million euro seed-fund managed by MS Ventures.

A highly experienced management team with strong expertise in drug development and an extensive scientific and industry network manages Calypso Biotech. We operate as a nimble, semi-virtual organization in order to create substantial added value for our investors from a portfolio of unique proprietary antibody candidates.